Table of Contents

Executive Summary

1 Kidney Cancer Drugs Market Overview

• 1.1 Product Overview and Scope of Kidney Cancer Drugs
• 1.2 Kidney Cancer Drugs Segment by Type
  • 1.2.1 Global Kidney Cancer Drugs Production Growth Rate Comparison by Type (2014-2025)
  • 1.2.2 Angiogenesis Inhibitors
  • 1.2.3 mTOR Inhibitors
  • 1.2.4 Monoclonal Antibodies
  • 1.2.5 Cytokine Immunotherapy (IL-2)
• 1.3 Kidney Cancer Drugs Segment by Application
  • 1.3.1 Kidney Cancer Drugs Consumption Comparison by Application (2014-2025)
  • 1.3.2 Renal cell carcinoma (RCC)
  • 1.3.3 Transitional cell carcinoma (TCC)
• 1.4 Global Kidney Cancer Drugs Market by Region
  • 1.4.1 Global Kidney Cancer Drugs Market Size Region
  • 1.4.2 North America Status and Prospect (2014-2025)
  • 1.4.3 Europe Status and Prospect (2014-2025)
  • 1.4.4 China Status and Prospect (2014-2025)
  • 1.4.5 Japan Status and Prospect (2014-2025)
• 1.5 Global Kidney Cancer Drugs Market Size
  • 1.5.1 Global Kidney Cancer Drugs Revenue (2014-2025)
  • 1.5.2 Global Kidney Cancer Drugs Production (2014-2025)

2 Global Kidney Cancer Drugs Market Competition by Manufacturers

• 2.1 Global Kidney Cancer Drugs Production Market Share by Manufacturers (2014-2019)
• 2.2 Global Kidney Cancer Drugs Revenue Share by Manufacturers (2014-2019)
• 2.3 Global Kidney Cancer Drugs Average Price by Manufacturers (2014-2019)
• 2.4 Manufacturers Kidney Cancer Drugs Production Sites, Area Served, Product Types
• 2.5 Kidney Cancer Drugs Market Competitive Situation and Trends
  • 2.5.1 Kidney Cancer Drugs Market Concentration Rate
  • 2.5.2 Kidney Cancer Drugs Market Share of Top 3 and Top 5 Manufacturers
  • 2.5.3 Mergers & Acquisitions, Expansion

3 Global Kidney Cancer Drugs Production Market Share by Regions

• 3.1 Global Kidney Cancer Drugs Production Market Share by Regions
• 3.2 Global Kidney Cancer Drugs Revenue Market Share by Regions (2014-2019)
• 3.3 Global Kidney Cancer Drugs Production, Revenue, Price and Gross Margin (2014-2019)
• 3.4 North America Kidney Cancer Drugs Production
  • 3.4.1 North America Kidney Cancer Drugs Production Growth Rate (2014-2019)
  • 3.4.2 North America Kidney Cancer Drugs Production, Revenue, Price and Gross Margin (2014-2019)
• 3.5 Europe Kidney Cancer Drugs Production
  • 3.5.1 Europe Kidney Cancer Drugs Production Growth Rate (2014-2019)
  • 3.5.2 Europe Kidney Cancer Drugs Production, Revenue, Price and Gross Margin (2014-2019)
• 3.6 China Kidney Cancer Drugs Production (2014-2019)
  • 3.6.1 China Kidney Cancer Drugs Production Growth Rate (2014-2019)
  • 3.6.2 China Kidney Cancer Drugs Production, Revenue, Price and Gross Margin (2014-2019)
• 3.7 Japan Kidney Cancer Drugs Production (2014-2019)
  • 3.7.1 Japan Kidney Cancer Drugs Production Growth Rate (2014-2019)
  • 3.7.2 Japan Kidney Cancer Drugs Production, Revenue, Price and Gross Margin (2014-2019)

4 Global Kidney Cancer Drugs Consumption by Regions

• 4.1 Global Kidney Cancer Drugs Consumption by Regions
• 4.2 North America Kidney Cancer Drugs Consumption (2014-2019)
• 4.3 Europe Kidney Cancer Drugs Consumption (2014-2019)
• 4.4 China Kidney Cancer Drugs Consumption (2014-2019)
• 4.5 Japan Kidney Cancer Drugs Consumption (2014-2019)

5 Global Kidney Cancer Drugs Production, Revenue, Price Trend by Type

• 5.1 Global Kidney Cancer Drugs Production Market Share by Type (2014-2019)
• 5.2 Global Kidney Cancer Drugs Revenue Market Share by Type (2014-2019)
• 5.3 Global Kidney Cancer Drugs Price by Type (2014-2019)
• 5.4 Global Kidney Cancer Drugs Production Growth by Type (2014-2019)

6 Global Kidney Cancer Drugs Market Analysis by Applications

• 6.1 Global Kidney Cancer Drugs Consumption Market Share by Application (2014-2019)
• 6.2 Global Kidney Cancer Drugs Consumption Growth Rate by Application (2014-2019)

7 Company Profiles and Key Figures in Kidney Cancer Drugs Business

• 7.1 Bayer
  • 7.1.1 Bayer Kidney Cancer Drugs Production Sites and Area Served
  • 7.1.2 Kidney Cancer Drugs Product Introduction, Application and Specification
  • 7.1.3 Bayer Kidney Cancer Drugs Production, Revenue, Price and Gross Margin (2014-2019)
  • 7.1.4 Main Business and Markets Served
• 7.2 Roche
  • 7.2.1 Roche Kidney Cancer Drugs Production Sites and Area Served
  • 7.2.2 Kidney Cancer Drugs Product Introduction, Application and Specification
  • 7.2.3 Roche Kidney Cancer Drugs Production, Revenue, Price and Gross Margin (2014-2019)
  • 7.2.4 Main Business and Markets Served
• 7.3 GlaxoSmithKline
  • 7.3.1 GlaxoSmithKline Kidney Cancer Drugs Production Sites and Area Served
  • 7.3.2 Kidney Cancer Drugs Product Introduction, Application and Specification
  • 7.3.3 GlaxoSmithKline Kidney Cancer Drugs Production, Revenue, Price and Gross Margin (2014-2019)
  • 7.3.4 Main Business and Markets Served
• 7.4 Novartis
  • 7.4.1 Novartis Kidney Cancer Drugs Production Sites and Area Served
  • 7.4.2 Kidney Cancer Drugs Product Introduction, Application and Specification
  • 7.4.3 Novartis Kidney Cancer Drugs Production, Revenue, Price and Gross Margin (2014-2019)
  • 7.4.4 Main Business and Markets Served
• 7.5 Pfizer
  • 7.5.1 Pfizer Kidney Cancer Drugs Production Sites and Area Served
  • 7.5.2 Kidney Cancer Drugs Product Introduction, Application and Specification
  • 7.5.3 Pfizer Kidney Cancer Drugs Production, Revenue, Price and Gross Margin (2014-2019)
  • 7.5.4 Main Business and Markets Served
• 7.6 Abbott Laboratories
  • 7.6.1 Abbott Laboratories Kidney Cancer Drugs Production Sites and Area Served
  • 7.6.2 Kidney Cancer Drugs Product Introduction, Application and Specification
  • 7.6.3 Abbott Laboratories Kidney Cancer Drugs Production, Revenue, Price and Gross Margin (2014-2019)
  • 7.6.4 Main Business and Markets Served
• 7.7 Active Biotech
  • 7.7.1 Active Biotech Kidney Cancer Drugs Production Sites and Area Served
  • 7.7.2 Kidney Cancer Drugs Product Introduction, Application and Specification
  • 7.7.3 Active Biotech Kidney Cancer Drugs Production, Revenue, Price and Gross Margin (2014-2019)
  • 7.7.4 Main Business and Markets Served
• 7.8 Amgen
  • 7.8.1 Amgen Kidney Cancer Drugs Production Sites and Area Served
  • 7.8.2 Kidney Cancer Drugs Product Introduction, Application and Specification
  • 7.8.3 Amgen Kidney Cancer Drugs Production, Revenue, Price and Gross Margin (2014-2019)
  • 7.8.4 Main Business and Markets Served
• 7.9 Argos Therapeutics
  • 7.9.1 Argos Therapeutics Kidney Cancer Drugs Production Sites and Area Served
  • 7.9.2 Kidney Cancer Drugs Product Introduction, Application and Specification
  • 7.9.3 Argos Therapeutics Kidney Cancer Drugs Production, Revenue, Price and Gross Margin (2014-2019)
  • 7.9.4 Main Business and Markets Served
• 7.10 ArQule
  • 7.10.1 ArQule Kidney Cancer Drugs Production Sites and Area Served
  • 7.10.2 Kidney Cancer Drugs Product Introduction, Application and Specification
  • 7.10.3 ArQule Kidney Cancer Drugs Production, Revenue, Price and Gross Margin (2014-2019)
  • 7.10.4 Main Business and Markets Served
• 7.11 AVEO Pharmaceuticals
• 7.12 Bionomics
• 7.13 Bristol-Myers Squibb
• 7.14 Cerulean Pharma
• 7.15 Exelixis
• 7.16 Genentech
• 7.17 immatics biotechnologies
• 7.18 Immunicum
• 7.19 Ono Pharmaceutical
• 7.20 Onyx Therapeutics
• 7.21 Oxford BioMedica
• 7.22 Prometheus Laboratories
• 7.23 Seattle Genetics
• 7.24 Taiwan Liposome
• 7.25 Tracon Pharmaceuticals
• 7.26 Wilex

8 Kidney Cancer Drugs Manufacturing Cost Analysis

• 8.1 Kidney Cancer Drugs Key Raw Materials Analysis
  • 8.1.1 Key Raw Materials
  • 8.1.2 Price Trend of Key Raw Materials
  • 8.1.3 Key Suppliers of Raw Materials
• 8.2 Proportion of Manufacturing Cost Structure
• 8.3 Manufacturing Process Analysis of Kidney Cancer Drugs
• 8.4 Kidney Cancer Drugs Industrial Chain Analysis

9 Marketing Channel, Distributors and Customers

• 9.1 Marketing Channel
  • 9.1.1 Direct Marketing
  • 9.1.2 Indirect Marketing
• 9.2 Kidney Cancer Drugs Distributors List
• 9.3 Kidney Cancer Drugs Customers

10 Market Dynamics

• 10.1 Market Trends
• 10.2 Opportunities
• 10.3 Market Drivers
• 10.4 Challenges
• 10.5 Influence Factors

11 Global Kidney Cancer Drugs Market Forecast

• 11.1 Global Kidney Cancer Drugs Production, Revenue Forecast
  • 11.1.1 Global Kidney Cancer Drugs Production Growth Rate Forecast (2019-2025)
  • 11.1.2 Global Kidney Cancer Drugs Revenue and Growth Rate Forecast (2019-2025)
  • 11.1.3 Global Kidney Cancer Drugs Price and Trend Forecast (2019-2025)
• 11.2 Global Kidney Cancer Drugs Production Forecast by Regions (2019-2025)
  • 11.2.1 North America Kidney Cancer Drugs Production, Revenue Forecast (2019-2025)
  • 11.2.2 Europe Kidney Cancer Drugs Production, Revenue Forecast (2019-2025)
  • 11.2.3 China Kidney Cancer Drugs Production, Revenue Forecast (2019-2025)
  • 11.2.4 Japan Kidney Cancer Drugs Production, Revenue Forecast (2019-2025)
• 11.3 Global Kidney Cancer Drugs Consumption Forecast by Regions (2019-2025)
  • 11.3.1 North America Kidney Cancer Drugs Consumption Forecast (2019-2025)
  • 11.3.2 Europe Kidney Cancer Drugs Consumption Forecast (2019-2025)
  • 11.3.3 China Kidney Cancer Drugs Consumption Forecast (2019-2025)
  • 11.3.4 Japan Kidney Cancer Drugs Consumption Forecast (2019-2025)
• 11.4 Global Kidney Cancer Drugs Production, Revenue and Price Forecast by Type (2019-2025)
• 11.5 Global Kidney Cancer Drugs Consumption Forecast by Application (2019-2025)

12 Research Findings and Conclusion

13 Methodology and Data Source

• 13.1 Methodology/Research Approach
  • 13.1.1 Research Programs/Design
  • 13.1.2 Market Size Estimation
  • 13.1.3 Market Breakdown and Data Triangulation
• 13.2 Data Source
  • 13.2.1 Secondary Sources
  • 13.2.2 Primary Sources
• 13.3 Author List

Kidney cancer, also known as renal cancer, is a type of cancer that starts in the cells in the kidney. The two most common types of kidney cancer are renal cell carcinoma (RCC) and transitional cell carcinoma (TCC) of the renal pelvis. These names reflect the type of cell from which the cancer developed. The different types of kidney cancer (such as RCC and TCC) develop in different ways, meaning that the diseases have different long term outcomes, and need to be staged and treated in different ways. RCC is responsible for approximately 80% of primary renal cancers, and TCC accounts the majority of the remainder.
Biological therapies are drugs which are used to kill cancer cells or stop them from growing. Biological therapies are used to try to shrink or control advanced kidney cancer and help people to live longer. You may be given biological therapies for kidney cancer that has already spread, or is at high-risk of coming back after surgery.

The global Kidney Cancer Drugs market is valued at xx million US$ in 2018 is expected to reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Kidney Cancer Drugs volume and value at global level, regional level and company level. From a global perspective, this report represents overall Kidney Cancer Drugs market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan.
At company level, this report focuses on the production capacity, ex-factory price, revenue and market share for each manufacturer covered in this report.

The following manufacturers are covered:
Bayer
Roche
GlaxoSmithKline
Novartis
Pfizer
Abbott Laboratories
Active Biotech
Amgen
Argos Therapeutics
ArQule
AVEO Pharmaceuticals
Bionomics
Bristol-Myers Squibb
Cerulean Pharma
Exelixis
Genentech
immatics biotechnologies
Immunicum
Ono Pharmaceutical
Onyx Therapeutics
Oxford BioMedica
Prometheus Laboratories
Seattle Genetics
Taiwan Liposome
Tracon Pharmaceuticals
Wilex

Segment by Regions
North America
Europe
China
Japan

Segment by Type
Angiogenesis Inhibitors
mTOR Inhibitors
Monoclonal Antibodies
Cytokine Immunotherapy (IL-2)

Segment by Application
Renal cell carcinoma (RCC)
Transitional cell carcinoma (TCC)